For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.

A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

Dr. Stephen Hauser was a young resident at Harvard when he met his first patient with multiple sclerosis, a woman with a thriving professional life who’d been completely wiped out by her condition, ...

MS is an autoimmune disorder in which the immune system attacks myelin, the protective covering of nerve fibres in the brain ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system, including the brain, spinal cord, and optic nerves. The body mistakenly attacks and damages the protective ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

The University of Virginia’s (UVA) health system has become one of the first in the country to administer a groundbreaking FDA-approved drug, Ocrevus Zunovo, to patients with progressive types of ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...